Peptris Technologies, a Bengaluru-based AI drug discovery company, will receive Rs 86 crore from the Technology Development Board (TDB) of India’s Department of Science and Technology (DST) under the Research Development and Innovation (RDI) Fund. The money will fund a three-year programme called VIGOR, which aims to move four AI-discovered drug candidates from early lab validation towards clinical trials. The agreement, announced on October 12, 2026, is one of the clearest signs yet that the Indian government will back AI in core science, not only in software.
What did TDB and Peptris announce?
The Technology Development Board signed an agreement with Peptris Technologies to provide Rs 86 crore, half of the programme’s Rs 172 crore total cost. The support comes from the government’s RDI Fund, which backs technology-intensive projects, and is structured as optionally convertible debt.
VIGOR is built around four experimental drugs that Peptris’s AI platform identified. According to the announcement, the goal is to advance each of them from TRL-4 to TRL-6 over three years. In plain terms, that means taking molecules that have shown promise in early validation and carrying them through advanced preclinical studies to the point where they are ready for clinical trials.
Which drugs are in the VIGOR programme?
The four candidates target conditions with limited treatment options:
- PEPR111: neuromuscular disorders and cancer
- PEPRX101: alopecia (hair loss)
- PEPR202: neuropathy
- PEPR112: listed as DMD. One report expands this as diabetes mellitus, but DMD normally stands for Duchenne muscular dystrophy, which fits better alongside a neuromuscular candidate. Peptris has not been quoted clarifying this in the coverage we reviewed.
All four are currently at TRL-4. TRL is a nine-point scale for technology maturity, and the move to TRL-6 means working on the stages that sit between a computational discovery and a first human trial.
What will the three years of funding pay for?
The announcement describes a structured programme that includes:
- Advanced preclinical studies to test safety and effectiveness in lab and animal models.
- Investigational New Drug (IND)-enabling studies, the data package regulators need before approving a first clinical trial.
- Formulation development, turning a molecule into a form that can be given to patients.
- Clinical trial preparation and initiation activities, subject to scientific and regulatory requirements.
Peptris will pair its AI platform with established drug development expertise, including a global network of contract research organisations (CROs) for development and validation work. This matches the company’s existing virtual model, where discovery happens in-house and wet-lab work is outsourced.
What did officials say?
Rajesh Kumar Pathak, Secretary of TDB, said the use of AI in pharmaceutical research could change how new drugs are found and developed, but that turning discoveries into proven treatments needs sustained investment, rigorous evaluation and a structured process. He described the RDI Fund as a way of bridging the gap between innovation and clinical development while building India’s capabilities in biotechnology, pharmaceuticals and AI-based healthcare.
A Peptris representative said the funding will help take AI-discovered molecules into critical preclinical stages and support the effort to translate computational discoveries into therapeutics that can move towards clinical development.
Who is Peptris Technologies?
Peptris is a Bengaluru-based startup that uses AI to discover drug candidates. It raised a $1 million pre-seed round led by Speciale Invest and, in early 2026, raised Rs 70 crore in a Series A round. The new TDB funding is therefore larger than that Series A and targets the expensive stage after discovery, where many startups run out of money.
It operates in a growing Indian field that includes startups such as ImmunitoAI, Boltzmann, Medvolt and AarogyaAI.
Why does this matter for India’s tech industry?
1. The government is funding the expensive middle of drug development
Many AI-bio startups can generate promising molecules. Far fewer can pay for the preclinical work that follows. By backing that stage, TDB is addressing the gap where discovery projects usually stall. It also signals that the RDI Fund will support applied AI projects that carry real scientific and regulatory risk.
2. It treats AI as deep tech, not just software
India’s AI story has largely been about IT services, SaaS and generative AI applications. A government-backed programme for AI-discovered drugs shows AI being used as a tool for core science, which could shift how investors and policymakers see the sector.
3. It moves AI drug discovery from platforms to pipelines
With named candidates, defined readiness milestones and a three-year timeline, Peptris can now be judged on assets and results, not platform claims. That is a harder test, and a more credible one.
4. It creates demand for hybrid talent
Programmes like VIGOR need data scientists, medicinal chemists, biologists, toxicologists and regulatory specialists. Indian CROs and research partners could see more work, and people who combine computational and lab skills will be in demand.
5. It supports India’s push beyond generics
India is one of the world’s largest producers of generic medicines but has a thinner record in original drug discovery. Using AI to lower early discovery costs is one route up the value chain, though one agreement will not change that on its own.
What are the risks and open questions?
- Funding is not success. Most preclinical candidates fail before or during human trials. Reaching TRL-6 does not mean an approved drug.
- It is debt, not a grant. Optionally convertible debt can be repaid or converted to equity, so the terms matter for Peptris’s future ownership and cash flow.
- The scope is one company. A single agreement is not a national strategy. The signal strengthens if the RDI Fund backs more projects of this kind.
- Details remain thin. Public reports do not yet give the disclosed targets, trial plans or timelines beyond the three-year window.
Frequently asked questions
How much funding did Peptris receive from TDB? Peptris will receive Rs 86 crore from the Technology Development Board under the RDI Fund, out of a total project cost of Rs 172 crore.
What is the VIGOR programme? VIGOR (Moving AI-Discovered Molecules from the Lab to the Clinic) is a three-year Peptris programme to advance four AI-discovered drug candidates from TRL-4 to TRL-6, covering preclinical development and clinical trial preparation.
What is the RDI Fund? The Research Development and Innovation (RDI) Fund is a government fund that supports technology-intensive research and development projects. In this case, it is disbursed through TDB as optionally convertible debt.
Is the funding a grant or a loan? It is optionally convertible debt, a financing instrument that can be repaid or converted into equity depending on the agreed terms. It is not a grant.
Which diseases do the four drug candidates target? The candidates target neuromuscular disorders and cancer (PEPR111), alopecia (PEPRX101), neuropathy (PEPR202), and a condition listed as DMD (PEPR112).
Does this mean India will have an AI-discovered drug soon? Not soon. The programme runs for three years and prepares candidates for clinical trials. Human trials and regulatory approval would take considerably longer.
What is TRL in drug development? Technology Readiness Level is a scale from 1 to 9 describing how mature a technology is. Moving from TRL-4 to TRL-6 means progressing from early lab validation to a demonstrated, trial-ready candidate.
Found this article interesting? Subscribe to The Innovators Jam for news, views, and write-ups on innovation, science, future-tech and research.
Follow us: Instagram @theinnovatorsjam, Youtube @InnovatorsJam, LinkedIn @ The Innovators Jam
We would love to hear from you. Leave your reply here.